Paulo Eduardo Stanga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paulo Eduardo Stanga has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- David Barry Henson
Manchester Royal Eye Hospital, Manchester, UK
6 shared publications George R. Marcellino
OptiMedica Corporation, Santa Clara, California, USA
4 shared publicationsStephen J. Charles
Manchester Royal Eye Hospital, Manchester, United Kingdom
4 shared publicationsDavid McLeod
Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
3 shared publicationsLorna B. Young
Manchester Royal Eye Hospital, Manchester, UK
3 shared publicationsMahiul M. K. Muqit
Manchester Royal Eye Hospital, Manchester, UK
3 shared publications
Latest Publications
- Open Access
- 6 June 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (6) , e0178462
Performance analysis of a new hypersonic vitrector system
To evaluate porcine vitreous flow and water flow rates in a new prototype hypersonic vitrectomy system compared to currently available pneumatic guillotine vitrectors (GVs) systems. Two vitrectors were tested, a prototype, ultrasound-powered, hypersonic vitrector (HV) and a GV. Porcine vitreous was obtained within 12 to 24 h of sacrifice and kept at 4°C. A vial of vitreous or water was placed on a precision balance and its weight measured before and after the use of each vitrector. Test parameters included changes in aspiration levels, vitrector gauge, cut rates for GVs, % ultrasound (US) power for HVs, and port size for HVs. Data was analysed using linear regression and t-tests. There was no difference in the total average mean water flow between the 25-gauge GV and the 25-gauge HV (t-test: P = 0.363); however, 25-gauge GV was superior (t-test: P < 0.001) in vitreous flow. The 23-gauge GV was only more efficient in water and vitreous removal than 23-gauge HV needle-1 (Port 0.0055) (t-test: P < 0.001). For HV, wall thickness and gauge had no effect on flow rates. Water and vitreous flows showed a direct correlation with increasing aspiration levels and % US power (p<0.05). The HV produced consistent water and vitreous flow rates across the range of US power and aspiration levels tested. Hypersonic vitrectomy may be a promising new alternative to the currently available guillotine-based technologies.
- 6 June 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (6) , e0178462
Open AccessPerformance analysis of a new hypersonic vitrector system
To evaluate porcine vitreous flow and water flow rates in a new prototype hypersonic vitrectomy system compared to currently available pneumatic guillotine vitrectors (GVs) systems. Two vitrectors were tested, a prototype, ultrasound-powered, hypersonic vitrector (HV) and a GV. Porcine vitreous was obtained within 12 to 24 h of sacrifice and kept at 4°C. A vial of vitreous or water was placed on a precision balance and its weight measured before and after the use of each vitrector. Test parameters included changes in aspiration levels, vitrector gauge, cut rates for GVs, % ultrasound (US) power for HVs, and port size for HVs. Data was analysed using linear regression and t-tests. There was no difference in the total average mean water flow between the 25-gauge GV and the 25-gauge HV (t-test: P = 0.363); however, 25-gauge GV was superior (t-test: P < 0.001) in vitreous flow. The 23-gauge GV was only more efficient in water and vitreous removal than 23-gauge HV needle-1 (Port 0.0055) (t-test: P < 0.001). For HV, wall thickness and gauge had no effect on flow rates. Water and vitreous flows showed a direct correlation with increasing aspiration levels and % US power (p<0.05). The HV produced consistent water and vitreous flow rates across the range of US power and aspiration levels tested. Hypersonic vitrectomy may be a promising new alternative to the currently available guillotine-based technologies.
- 26 May 2017
- Published by Springer Nature in Eye
- Vol. 31 (10) , 1383-1398
Electronic retinal implants and artificial vision: journey and present
Retinitis pigmentosa and age-related macular degeneration are two significant causes of severe visual dysfunction. In both, the retinal photoreceptors degenerate, preventing successful conversion of light into electrical energy that is interpreted in the visual cortex as visual function. Artificial vision or visual function began over two centuries ago with the idea of creating artificial light pulses, or phosphenes, through cortical stimulation. The pursuit is now on to improve artificial visual function. Two retinal implants appear the most likely to succeed in the future having undergone multicentre human trials: the Argus II electronic epiretinal device (Second Sight Medical Products, CA, USA) and Alpha-IMS electronic subretinal device (Retina Implant AG, Germany). The trial results to date are encouraging with visual improvement and acceptable safety profiles reported for both devices. At present, the visual function generated by either device does not offer high enough resolution or acuity for a patient to regain a fully functional life. Despite this, both devices not only have the potential, but have actually improved the vision-related quality of life in a significant number of patients implanted. With this in mind, the economic argument is clear. Provided device-life is long enough, its cost should be acceptable for the obtained improvement in the quality of life. The aim of this Review Article is to assist those readers that may be considering offering any of these devices as a treatment for blindness in Retinitis Pigmentosa.
- 26 May 2017
- Published by Springer Nature in Eye
- Vol. 31 (10) , 1383-1398
Electronic retinal implants and artificial vision: journey and present
Retinitis pigmentosa and age-related macular degeneration are two significant causes of severe visual dysfunction. In both, the retinal photoreceptors degenerate, preventing successful conversion of light into electrical energy that is interpreted in the visual cortex as visual function. Artificial vision or visual function began over two centuries ago with the idea of creating artificial light pulses, or phosphenes, through cortical stimulation. The pursuit is now on to improve artificial visual function. Two retinal implants appear the most likely to succeed in the future having undergone multicentre human trials: the Argus II electronic epiretinal device (Second Sight Medical Products, CA, USA) and Alpha-IMS electronic subretinal device (Retina Implant AG, Germany). The trial results to date are encouraging with visual improvement and acceptable safety profiles reported for both devices. At present, the visual function generated by either device does not offer high enough resolution or acuity for a patient to regain a fully functional life. Despite this, both devices not only have the potential, but have actually improved the vision-related quality of life in a significant number of patients implanted. With this in mind, the economic argument is clear. Provided device-life is long enough, its cost should be acceptable for the obtained improvement in the quality of life. The aim of this Review Article is to assist those readers that may be considering offering any of these devices as a treatment for blindness in Retinitis Pigmentosa.
- Open Access
- 11 April 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (4) , e0173883
Ultrastructural and histopathologic findings after pars plana vitrectomy with a new hypersonic vitrector system. Qualitative preliminary assessment
Preliminary assessment of a new prototype ultrasound-based hypersonic vitrector (HV) by qualitatively examining the histopathological changes in the retina and vitreous body after pars plana vitrectomy (PPV) and its ability to fragment vitreous collagen. Fourteen porcine cadaveric eyes, 20 eyes in live swine and six human cadaveric eyes underwent PPV using the HV or a pneumatic guillotine vitrector (GV). An additional 4 porcine crystalline lenses were touched with either the HV or GV for 1 minute. Following PPV, human vitreous was removed and processed for electron microscopy (EM). Eyes and lenses were fixed and sectioned for light microscopy (LM). There were no macroscopic retinal or optic nerve defects associated with either HV or GV PPVs. Cadaveric retinal specimens showed separation of the inner limiting membrane (ILM) and vacuolization and fragmentation at the nerve fiber layer (NFL) and the ganglion cell layer (GCL). ILM fragmentation and separation were found after PPV in live swine with both vitrectors. Small disruptions of the posterior capsule or structural lens defects were found after HV touch. The EM analysis revealed more fragmentation of human vitreous collagen fibrils after HV compared to GV PPV. LM and EM analysis of retina, vitreous, and crystalline lens after PPV showed similar morphological changes using the HV or the GV. Vitreous fragmentation appeared more effective with the HV. Overall this study suggests that the HV may be a promising new technology. More work is needed to quantitatively assess its safety and efficacy.
- 11 April 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (4) , e0173883
Open AccessUltrastructural and histopathologic findings after pars plana vitrectomy with a new hypersonic vitrector system. Qualitative preliminary assessment
Preliminary assessment of a new prototype ultrasound-based hypersonic vitrector (HV) by qualitatively examining the histopathological changes in the retina and vitreous body after pars plana vitrectomy (PPV) and its ability to fragment vitreous collagen. Fourteen porcine cadaveric eyes, 20 eyes in live swine and six human cadaveric eyes underwent PPV using the HV or a pneumatic guillotine vitrector (GV). An additional 4 porcine crystalline lenses were touched with either the HV or GV for 1 minute. Following PPV, human vitreous was removed and processed for electron microscopy (EM). Eyes and lenses were fixed and sectioned for light microscopy (LM). There were no macroscopic retinal or optic nerve defects associated with either HV or GV PPVs. Cadaveric retinal specimens showed separation of the inner limiting membrane (ILM) and vacuolization and fragmentation at the nerve fiber layer (NFL) and the ganglion cell layer (GCL). ILM fragmentation and separation were found after PPV in live swine with both vitrectors. Small disruptions of the posterior capsule or structural lens defects were found after HV touch. The EM analysis revealed more fragmentation of human vitreous collagen fibrils after HV compared to GV PPV. LM and EM analysis of retina, vitreous, and crystalline lens after PPV showed similar morphological changes using the HV or the GV. Vitreous fragmentation appeared more effective with the HV. Overall this study suggests that the HV may be a promising new technology. More work is needed to quantitatively assess its safety and efficacy.
- Open Access
- 28 November 2016
- Published by MedCrave Group Kft. in Advances in Ophthalmology & Visual System
- Vol. 5 (3) , 1-8
Swept-Source Optical Coherence Tomography Assessment of the Posterior Cortical Vitreous and Choroidal Thickness in Different Macular Disorders
Purpose: Swept-Source Optical Coherence Tomography (SS-OCT) determination of the prevalence of the Bursa Premacularis (BPM) and Space of Martegiani (SM) and assessment of Choroidal Thickness (CT) in healthy eyes (HE) and eyes with various macular disorders (MD). Methods: Retrospective, comparative and non-interventional study. 134 non-consecutive patients underwent 1,050nm SS-OCT (DRI-OCT1 Atlantis®, Topcon Corp, and Japan). The prevalence of the BPM and SM was assessed in HE and MD patients. Macular CT was determined by measuring the distance between the RPE and the choroid/sclera junction at seven measurements (one subfoveal, three further determinations every 500µm up to 1500 µm temporal (T1, T2, T3) and nasal (N1, N2, N3) to fovea of 54 HE and 150 MD. Patients were categorised into 8 groups; (Diabetic Retinopathy (53), age-related macular degeneration (AMD) (32), High myopia (HM) (22), vitreomacular adhesion (VMA) and/ or vitreomacular traction (VTM) (11), central serous retinopathy (CSR) (13), retinitis pigmentosa (RP) (9) and Miscellaneous (10). Results: Mean age was 47±23 years for HE versus 57±22 years for MD (p<0.05). Mean sub-foveal CT was 289±75 μm for HE versus 223±84 μm for MD (p=0.009). BPM was detected in 36 out of 54 eyes of HE (66.7%); 95% confidence intervals (CI) [0.54-0.78] versus 51 out of 150 eyes (34.0%) of MD; 95% CI [0.27-0.41]; (p=0.001). SM was present in of 30 out of 54 eyes of HE (55.6%); 95% CI [0.42-0.68] versus 49 out of 150 eyes of MD (32.7%) (p=0.004). Subgroup analysis showed significant differences in CT between HE and MD with Diabetic Retinopathy, AMD, HM, CRS and VMA and/or VTM (p<0.05) Conclusion: SS-OCT allows the measurement of CT in different macular anomalies and the assessment of the cortical vitreous and prevalence of the BPM and SM. The BPM and SM were more prevalent in HE. A thin choroid may be associated with Diabetic Retinopathy, AMD, High Myopia and VMA/VTM groups and a thick one with CSR group.
- 28 November 2016
- Published by MedCrave Group Kft. in Advances in Ophthalmology & Visual System
- Vol. 5 (3) , 1-8
Open AccessSwept-Source Optical Coherence Tomography Assessment of the Posterior Cortical Vitreous and Choroidal Thickness in Different Macular Disorders
Purpose: Swept-Source Optical Coherence Tomography (SS-OCT) determination of the prevalence of the Bursa Premacularis (BPM) and Space of Martegiani (SM) and assessment of Choroidal Thickness (CT) in healthy eyes (HE) and eyes with various macular disorders (MD). Methods: Retrospective, comparative and non-interventional study. 134 non-consecutive patients underwent 1,050nm SS-OCT (DRI-OCT1 Atlantis®, Topcon Corp, and Japan). The prevalence of the BPM and SM was assessed in HE and MD patients. Macular CT was determined by measuring the distance between the RPE and the choroid/sclera junction at seven measurements (one subfoveal, three further determinations every 500µm up to 1500 µm temporal (T1, T2, T3) and nasal (N1, N2, N3) to fovea of 54 HE and 150 MD. Patients were categorised into 8 groups; (Diabetic Retinopathy (53), age-related macular degeneration (AMD) (32), High myopia (HM) (22), vitreomacular adhesion (VMA) and/ or vitreomacular traction (VTM) (11), central serous retinopathy (CSR) (13), retinitis pigmentosa (RP) (9) and Miscellaneous (10). Results: Mean age was 47±23 years for HE versus 57±22 years for MD (p<0.05). Mean sub-foveal CT was 289±75 μm for HE versus 223±84 μm for MD (p=0.009). BPM was detected in 36 out of 54 eyes of HE (66.7%); 95% confidence intervals (CI) [0.54-0.78] versus 51 out of 150 eyes (34.0%) of MD; 95% CI [0.27-0.41]; (p=0.001). SM was present in of 30 out of 54 eyes of HE (55.6%); 95% CI [0.42-0.68] versus 49 out of 150 eyes of MD (32.7%) (p=0.004). Subgroup analysis showed significant differences in CT between HE and MD with Diabetic Retinopathy, AMD, HM, CRS and VMA and/or VTM (p<0.05) Conclusion: SS-OCT allows the measurement of CT in different macular anomalies and the assessment of the cortical vitreous and prevalence of the BPM and SM. The BPM and SM were more prevalent in HE. A thin choroid may be associated with Diabetic Retinopathy, AMD, High Myopia and VMA/VTM groups and a thick one with CSR group.
- 1 January 2016
- Published by Wolters Kluwer Health in Retina
- Vol. 36 (1) , 156-162
TRANSCLERAL DRAINAGE OF SUBRETINAL FLUID, ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR, AND WIDE-FIELD IMAGING-GUIDED LASER IN COATS EXUDATIVE RETINAL DETACHMENT
Purpose: To evaluate the safety and efficacy of combined transscleral drainage of subretinal fluid (SRF) with intravitreal bevacizumab and laser photocoagulation in the management of advanced Coats disease (Stage 3) with exudative retinal detachment. Design: Retrospective interventional case series. Methods: Retrospective case review of eight eyes in eight children with advanced Coats disease manifested as total or subtotal retinal detachment. All eyes initially underwent surgical drainage of exudative SRF followed by intravitreal injection of bevacizumab and laser photocoagulation. Patients were subsequently followed up for up to 60 months. Results: In all eyes, after SRF drainage and administration of one to two intravitreal injections, SRF was completely eliminated. Patients required up to four sessions of laser photocoagulation. Retinal detachment consequently reduced with all patients showing total retinal reattachment and resolution of the subretinal exudates. At the last follow-up, no patient showed recurrent SRF and no ocular complications related to bevacizumab nor evidence of further disease progression were noted. Conclusion: The authors present a new therapeutic approach that allows for the first time successful treatment of advanced cases of exudative retinal detachment in Coats disease without the need for vitrectomy. Transscleral drainage of SRF accompanied by anti-vascular endothelial growth factor injection and laser photocoagulation appears to be successful in halting progression of advanced Coats disease with exudative detachment and a less invasive approach when compared with conventional management.
- 1 January 2016
- Published by Wolters Kluwer Health in Retina
- Vol. 36 (1) , 156-162
TRANSCLERAL DRAINAGE OF SUBRETINAL FLUID, ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR, AND WIDE-FIELD IMAGING-GUIDED LASER IN COATS EXUDATIVE RETINAL DETACHMENT
Purpose: To evaluate the safety and efficacy of combined transscleral drainage of subretinal fluid (SRF) with intravitreal bevacizumab and laser photocoagulation in the management of advanced Coats disease (Stage 3) with exudative retinal detachment. Design: Retrospective interventional case series. Methods: Retrospective case review of eight eyes in eight children with advanced Coats disease manifested as total or subtotal retinal detachment. All eyes initially underwent surgical drainage of exudative SRF followed by intravitreal injection of bevacizumab and laser photocoagulation. Patients were subsequently followed up for up to 60 months. Results: In all eyes, after SRF drainage and administration of one to two intravitreal injections, SRF was completely eliminated. Patients required up to four sessions of laser photocoagulation. Retinal detachment consequently reduced with all patients showing total retinal reattachment and resolution of the subretinal exudates. At the last follow-up, no patient showed recurrent SRF and no ocular complications related to bevacizumab nor evidence of further disease progression were noted. Conclusion: The authors present a new therapeutic approach that allows for the first time successful treatment of advanced cases of exudative retinal detachment in Coats disease without the need for vitrectomy. Transscleral drainage of SRF accompanied by anti-vascular endothelial growth factor injection and laser photocoagulation appears to be successful in halting progression of advanced Coats disease with exudative detachment and a less invasive approach when compared with conventional management.
- Open Access
- 14 April 2014
- Published by Springer Nature in BMC Ophthalmology
- Vol. 14 (1) , 49
The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients
Retinitis Pigmentosa (RP) is a hereditary genetic disease causing bilateral retinal degeneration. RP is a leading cause of blindness resulting in incurable visual impairment and drastic reduction in the Quality of life of the patients. Second Sight Medical Products Inc. developed Argus II, a retinal prosthesis system for treating RP. Argus II is the world’s first ever-commercial implant intended to restore some vision in the blind patients. The objective of this study was to assess the cost-effectiveness of the Argus® II Retinal Prosthesis System (Argus II) in Retinitis Pigmentosa (RP) patients. A multi -state transition Markov model was developed to determine the cost-effectiveness of Argus II versus usual care in RP from the perspective of healthcare payer. A hypothetical cohort of 1000 RP patients aged 46 years followed up over a (lifetime) 25-year time horizon. Health outcomes were expressed as quality adjusted life years (QALYs) and direct healthcare costs expressed in 2012 €. Results are reported as incremental cost per ratios (ICERs) with outcomes and costs discounted at an annual rate of 3.5%. The ICER for Argus II was €14,603/QALY. Taking into account the uncertainty in model inputs the ICER was €14,482/QALY in the probabilistic analysis. In the scenarios of an assumption of no reduction on cost across model visual acuity states or a model time horizon as short as 10 years the ICER increased to €31,890/QALY and €49,769/QALY respectively. This economic evaluation shows that Argus II is a cost-effective intervention compared to usual care of the RP patients. The lifetime analysis ICER for Argus II falls below the published societal willingness to pay of EuroZone countries.
- 14 April 2014
- Published by Springer Nature in BMC Ophthalmology
- Vol. 14 (1) , 49
Open AccessThe cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients
Retinitis Pigmentosa (RP) is a hereditary genetic disease causing bilateral retinal degeneration. RP is a leading cause of blindness resulting in incurable visual impairment and drastic reduction in the Quality of life of the patients. Second Sight Medical Products Inc. developed Argus II, a retinal prosthesis system for treating RP. Argus II is the world’s first ever-commercial implant intended to restore some vision in the blind patients. The objective of this study was to assess the cost-effectiveness of the Argus® II Retinal Prosthesis System (Argus II) in Retinitis Pigmentosa (RP) patients. A multi -state transition Markov model was developed to determine the cost-effectiveness of Argus II versus usual care in RP from the perspective of healthcare payer. A hypothetical cohort of 1000 RP patients aged 46 years followed up over a (lifetime) 25-year time horizon. Health outcomes were expressed as quality adjusted life years (QALYs) and direct healthcare costs expressed in 2012 €. Results are reported as incremental cost per ratios (ICERs) with outcomes and costs discounted at an annual rate of 3.5%. The ICER for Argus II was €14,603/QALY. Taking into account the uncertainty in model inputs the ICER was €14,482/QALY in the probabilistic analysis. In the scenarios of an assumption of no reduction on cost across model visual acuity states or a model time horizon as short as 10 years the ICER increased to €31,890/QALY and €49,769/QALY respectively. This economic evaluation shows that Argus II is a cost-effective intervention compared to usual care of the RP patients. The lifetime analysis ICER for Argus II falls below the published societal willingness to pay of EuroZone countries.
- 1 February 2014
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 157 (2) , 397-404.e2
In Vivo Imaging of Cortical Vitreous Using 1050-nm Swept-Source Deep Range Imaging Optical Coherence Tomography
- 1 February 2014
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 157 (2) , 397-404.e2
In Vivo Imaging of Cortical Vitreous Using 1050-nm Swept-Source Deep Range Imaging Optical Coherence Tomography
- Open Access
- 28 February 2012
- Published by Wiley in Acta Ophthalmologica
- Vol. 90 (2) , 155-161
Study of clinical applications and safety for Pascal® laser photocoagulation in retinal vascular disorders
: Purpose: To establish safe laser parameter standards for 10–30 ms Pascal® laser in clinical practice and to evaluate clinical and visual outcomes using this 532‐nm multi‐spot photocoagulation system.Methods: Retrospective observational case series of 313 patients treated between 2006 and 2008. Evaluation of eight groups: A – panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR); B – focal laser treatment for clinically significant diabetic macular oedema; C – grid laser for diffuse diabetic macular oedema; D – sector PRP for ischaemic branch retinal vein occlusions (I‐BRVO); E – full PRP for ischaemic central retinal vein occlusions (I‐CRVO); F – macular laser treatment for macular oedema secondary to non‐ischaemic BRVO; G – full PRP for rubeosis iridis and/or neovascular glaucoma (NVG) secondary to I‐BRVO, I – CRVO or PDR; H – laser retinopexy for retinal breaks/degenerations.Results: Mean LogMAR visual acuity for all procedures improved postlaser (p = 0.065), and laser prevented visual loss in 85% eyes. Topical anaesthesia was only required. At mean follow‐up of 5 months, 72% procedures had a successful clinical outcome. Significantly higher powers were required for PRP using Pascal® compared to conventional laser (p = 0.001) in PDR, I‐BRVO, I‐CRVO and NVG. Sixty‐seven per cent of patients (15/20) were successfully treated with single‐session 20‐ms PRP using a mean 1952 burns. There were no laser‐associated adverse effects or ocular complications associated with multi‐spot PRP or macular Pascal® arrays.Conclusions: The clinical efficacy using 10‐ to 30‐ms pulse duration Pascal® laser is comparable to conventional standard protocols used for the treatment of vascular retinal disorders. Higher power, 10‐ to 30‐ms pulse duration laser may be safely and effectively used in clinical practice.
- 28 February 2012
- Published by Wiley in Acta Ophthalmologica
- Vol. 90 (2) , 155-161
Open AccessStudy of clinical applications and safety for Pascal® laser photocoagulation in retinal vascular disorders
: Purpose: To establish safe laser parameter standards for 10–30 ms Pascal® laser in clinical practice and to evaluate clinical and visual outcomes using this 532‐nm multi‐spot photocoagulation system.Methods: Retrospective observational case series of 313 patients treated between 2006 and 2008. Evaluation of eight groups: A – panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR); B – focal laser treatment for clinically significant diabetic macular oedema; C – grid laser for diffuse diabetic macular oedema; D – sector PRP for ischaemic branch retinal vein occlusions (I‐BRVO); E – full PRP for ischaemic central retinal vein occlusions (I‐CRVO); F – macular laser treatment for macular oedema secondary to non‐ischaemic BRVO; G – full PRP for rubeosis iridis and/or neovascular glaucoma (NVG) secondary to I‐BRVO, I – CRVO or PDR; H – laser retinopexy for retinal breaks/degenerations.Results: Mean LogMAR visual acuity for all procedures improved postlaser (p = 0.065), and laser prevented visual loss in 85% eyes. Topical anaesthesia was only required. At mean follow‐up of 5 months, 72% procedures had a successful clinical outcome. Significantly higher powers were required for PRP using Pascal® compared to conventional laser (p = 0.001) in PDR, I‐BRVO, I‐CRVO and NVG. Sixty‐seven per cent of patients (15/20) were successfully treated with single‐session 20‐ms PRP using a mean 1952 burns. There were no laser‐associated adverse effects or ocular complications associated with multi‐spot PRP or macular Pascal® arrays.Conclusions: The clinical efficacy using 10‐ to 30‐ms pulse duration Pascal® laser is comparable to conventional standard protocols used for the treatment of vascular retinal disorders. Higher power, 10‐ to 30‐ms pulse duration laser may be safely and effectively used in clinical practice.
- 16 December 2011
- Published by Wiley in Acta Ophthalmologica
- Vol. 91 (3) , 251-258
Optos‐guided pattern scan laser (Pascal)‐targeted retinal photocoagulation in proliferative diabetic retinopathy
: Purpose: To investigate the clinical effects and safety of targeted pattern scan laser (Pascal) retinal photocoagulation (TRP) in proliferative diabetic retinopathy (PDR).Methods: Prospective and non‐randomized study of 28 eyes with treatment‐naive proliferative diabetic retinopathy (PDR). Single‐session 20‐ms‐Pascal TRP strategy applied 1500 burns to zones of retinal capillary non‐perfusion and intermediate retinal ischaemia guided by wide‐field fluorescein angiography (Optos). Main outcome measures at 12 and 24 weeks included; PDR grade (assessed by two masked retina specialists); central retinal thickness (CRT); mean deviation (MD) using 24‐2 Swedish interactive threshold algorithm (SITA)‐standard visual fields (VF); and ETDRS visual acuity (VA).Results: Following primary TRP, there was PDR regression in 76% of patients at 12 weeks (κ = 0.70; p < 0.001). No laser re‐treatment was required at 4 weeks, and 10 eyes underwent repeat TRP at 12 weeks. Wide‐field Optos angiography at 24 weeks showed complete disease regression in 37% and partial regression in 33%. Additional panretinal laser photocoagulation (PRP) was planned for active PDR in 30%. There were significant reductions in CRT over time (10.4 μm at 12‐weeks, p = 0.007; 12.1 μm at 24‐weeks, p = 0.0003). The MD on VFs improved after 12 weeks (+1.25 dB; p = 0.015) and 24 weeks (+1.26 dB, p = 0.01). The VA increased by +3 letters at 24 weeks (95% CI, 1.74–5.01; p < 0.0001).Conclusions: This pilot study reports that Optos‐guided Pascal 20‐ms TRP using 1500 burns for treatment‐naive PDR is a promising procedure with favourable safety profile.
- 16 December 2011
- Published by Wiley in Acta Ophthalmologica
- Vol. 91 (3) , 251-258
Optos‐guided pattern scan laser (Pascal)‐targeted retinal photocoagulation in proliferative diabetic retinopathy
: Purpose: To investigate the clinical effects and safety of targeted pattern scan laser (Pascal) retinal photocoagulation (TRP) in proliferative diabetic retinopathy (PDR).Methods: Prospective and non‐randomized study of 28 eyes with treatment‐naive proliferative diabetic retinopathy (PDR). Single‐session 20‐ms‐Pascal TRP strategy applied 1500 burns to zones of retinal capillary non‐perfusion and intermediate retinal ischaemia guided by wide‐field fluorescein angiography (Optos). Main outcome measures at 12 and 24 weeks included; PDR grade (assessed by two masked retina specialists); central retinal thickness (CRT); mean deviation (MD) using 24‐2 Swedish interactive threshold algorithm (SITA)‐standard visual fields (VF); and ETDRS visual acuity (VA).Results: Following primary TRP, there was PDR regression in 76% of patients at 12 weeks (κ = 0.70; p < 0.001). No laser re‐treatment was required at 4 weeks, and 10 eyes underwent repeat TRP at 12 weeks. Wide‐field Optos angiography at 24 weeks showed complete disease regression in 37% and partial regression in 33%. Additional panretinal laser photocoagulation (PRP) was planned for active PDR in 30%. There were significant reductions in CRT over time (10.4 μm at 12‐weeks, p = 0.007; 12.1 μm at 24‐weeks, p = 0.0003). The MD on VFs improved after 12 weeks (+1.25 dB; p = 0.015) and 24 weeks (+1.26 dB, p = 0.01). The VA increased by +3 letters at 24 weeks (95% CI, 1.74–5.01; p < 0.0001).Conclusions: This pilot study reports that Optos‐guided Pascal 20‐ms TRP using 1500 burns for treatment‐naive PDR is a promising procedure with favourable safety profile.
- 1 September 2011
- Published by Wolters Kluwer Health in Retina
- Vol. 31 (8) , 1699-1707
RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFECTS OF PASCAL PANRETINAL PHOTOCOAGULATION ON MACULAR NERVE FIBER LAYER
Purpose: To investigate the effects of panretinal photocoagulation (PRP) on macular thickness and macular nerve fiber layer thickness in eyes with proliferative diabetic retinopathy. Methods: Single-center, randomized clinical trial (n = 40 eyes). Proliferative diabetic retinopathy was treated with 1,500 burns given as Pascal 20-millisecond single-session PRP (SS-PRP) or as multiple-session PRP (100 milliseconds, MS-PRP) over a 4-week period. The main outcome measures included optical coherence tomography measurements of total retinal thickness and nerve fiber layer at the macula, visual acuity, and proliferative diabetic retinopathy regression and were recorded at baseline, 4 weeks, and 12 weeks. Optic disk photographs were graded by masked a glaucoma specialist. Results: At 12 weeks, in the SS-PRP group, there was no significant change in total nerve fiber layer thickness from baseline (4 weeks; +7.2 mu m, P = 0.78; 12 weeks, -1.8 mu m, P = 0.95). There was a significant increase in total retinal thickness for the MS-PRP group at 4 weeks from baseline (96 +/- 17 mu m; P < 0.001) and at 12 weeks (56 +/- 21 mu m; P = 0.0167). After 4 weeks in the MS-PRP group, total nerve fiber layer thickness increased significantly by 31 +/- 54 mu m (P = 0.029) from baseline, with a significant reduction at 12 weeks from baseline (35 +/- 63 mu m; P = 0.034). There was no change among groups for optic nerve appearance postlaser. At 12 weeks, the mean visual acuity was 81 +/- 6 letters (SS-PRP group), compared with 77 +/- 15 letters in the MS-PRP group (95% confidence interval, 5.2 to 9 letters; P = 0.286). For the SS-PRP group, a positive effect on proliferative diabetic retinopathy regression was observed in 74% of eyes compared with 53% of the eyes in the MS-PRP group (P = 0.31). Conclusion: Compared with 20-millisecond SS-PRP, eyes treated with conventional 100-millisecond single-spot delivered over multiple sessions showed increased total macular thickness at 4 weeks, with a thinning of macular nerve fiber layer at 12 weeks. RETINA 31: 1699-1707, 2011
- 1 September 2011
- Published by Wolters Kluwer Health in Retina
- Vol. 31 (8) , 1699-1707
RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFECTS OF PASCAL PANRETINAL PHOTOCOAGULATION ON MACULAR NERVE FIBER LAYER
Purpose: To investigate the effects of panretinal photocoagulation (PRP) on macular thickness and macular nerve fiber layer thickness in eyes with proliferative diabetic retinopathy. Methods: Single-center, randomized clinical trial (n = 40 eyes). Proliferative diabetic retinopathy was treated with 1,500 burns given as Pascal 20-millisecond single-session PRP (SS-PRP) or as multiple-session PRP (100 milliseconds, MS-PRP) over a 4-week period. The main outcome measures included optical coherence tomography measurements of total retinal thickness and nerve fiber layer at the macula, visual acuity, and proliferative diabetic retinopathy regression and were recorded at baseline, 4 weeks, and 12 weeks. Optic disk photographs were graded by masked a glaucoma specialist. Results: At 12 weeks, in the SS-PRP group, there was no significant change in total nerve fiber layer thickness from baseline (4 weeks; +7.2 mu m, P = 0.78; 12 weeks, -1.8 mu m, P = 0.95). There was a significant increase in total retinal thickness for the MS-PRP group at 4 weeks from baseline (96 +/- 17 mu m; P < 0.001) and at 12 weeks (56 +/- 21 mu m; P = 0.0167). After 4 weeks in the MS-PRP group, total nerve fiber layer thickness increased significantly by 31 +/- 54 mu m (P = 0.029) from baseline, with a significant reduction at 12 weeks from baseline (35 +/- 63 mu m; P = 0.034). There was no change among groups for optic nerve appearance postlaser. At 12 weeks, the mean visual acuity was 81 +/- 6 letters (SS-PRP group), compared with 77 +/- 15 letters in the MS-PRP group (95% confidence interval, 5.2 to 9 letters; P = 0.286). For the SS-PRP group, a positive effect on proliferative diabetic retinopathy regression was observed in 74% of eyes compared with 53% of the eyes in the MS-PRP group (P = 0.31). Conclusion: Compared with 20-millisecond SS-PRP, eyes treated with conventional 100-millisecond single-spot delivered over multiple sessions showed increased total macular thickness at 4 weeks, with a thinning of macular nerve fiber layer at 12 weeks. RETINA 31: 1699-1707, 2011